Ovid Therapeutics Inc.
OVID· Nasdaq
Released May 13, 2025, before the open
10-Q filed May 13, 2025, 43 days after period end · 0001628280-25-024913
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $130.00K | $148.00K | $66.00K | $1.45M |
| Net Income | -$10.24M | -$11.69M | -$13.36M | -$16.11M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| — |
| -$0.17 |
| -$0.19 |
| -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.